Appili Therapeutics Advances with FDA Approvals and Funding

Appili Therapeutics Inc Class A (TSE:APLI) has released an update.

Appili Therapeutics Inc. has reported a milestone achievement with the FDA approval and subsequent commercial launch of LIKMEZ™, a metronidazole oral suspension for treating anaerobic bacterial infections. The company has also secured significant funding from the U.S. Air Force Academy to advance its biodefense vaccine candidate, ATI-1701, towards an IND submission. Additionally, Appili is progressing with its antiparasitic product, ATI-1801, which is in advanced clinical development and may qualify for a priority review voucher.

For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.